# EDGAR Filing Document

**Accession Number:** 0001680367
**File Stem:** 0001104659-25-074849
**Filing Date:** 2025-8
**Character Count:** 30136
**Document Hash:** 342867322b2f03b313a010c48184f6a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-074849.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0001104659-25-074849

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250806

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shattuck Labs, Inc.
- **CENTRAL INDEX KEY:** 0001680367
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 812575858
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91760
- **FILM NUMBER:** 251191256

**BUSINESS ADDRESS:**
- **STREET 1:** 500 W. 5TH STREET
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
- **BUSINESS PHONE:** 512-900-4690

**MAIL ADDRESS:**
- **STREET 1:** 500 W. 5TH STREET
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Redmile Group, LLC
- **CENTRAL INDEX KEY:** 0001425738

**ORGANIZATION NAME:**
- **EIN:** 208592298
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** ONE LETTERMAN DRIVE
- **STREET 2:** BUILDING D, SUITE D3-300
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94129
- **BUSINESS PHONE:** 415-489-9980

**MAIL ADDRESS:**
- **STREET 1:** ONE LETTERMAN DRIVE
- **STREET 2:** BUILDING D, SUITE D3-300
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94129

## Exhibit 99.8

Exhibit 99.8

***Execution***

 ****

August 4, 2025

Redmile Group, LLC

One Letterman Drive,

Building D, Suite D3-300

San Francisco, CA 94129

Attention: Redmile Legal

Re: Shattuck Labs, Inc. Participation and Observer Rights

 ****

Ladies and Gentlemen:

This letter agreement (this "**Letter Agreement**") memorializes the agreement and understanding between Redmile Group, LLC (collectively, together with their Affiliates, "**Redmile**") and Shattuck Labs, Inc., a Delaware corporation, and any successors and assigns (the "**Company**"), regarding the Company's grant to Redmile of the rights to (1) participate in the Company's future equity offerings of its equity securities on the terms, and subject to the conditions, set forth below, and (2) appoint one non-voting observer to the Board of Directors of the Company (the "**Board of Directors**").

The Company is entering into this Letter Agreement as a material inducement to cause Redmile to enter into that certain Securities Purchase Agreement, dated as of August 4, 2025 (the "**Purchase Agreement**"), by and among the Company and the investors listed on Exhibit A thereto. Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement, including in the form of Registration Rights Agreement attached as an exhibit thereto.

In consideration of the foregoing and the mutual promises and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, by execution of this Letter Agreement, the Company and Redmile hereby agree as follows:

1.  ***Future Equity Offerings Participation Right.*** The
Company shall, within a reasonable period of time preceding the consummation of any future equity offering (excluding a firm commitment
underwritten offering and sales by the Company pursuant to any "at-the-market" offering facility) (a "Future Equity
Offering"), and in compliance with all applicable laws and regulations, provide Redmile with the opportunity to purchase securities
offered in any Future Equity Offering (such right, the "**Future Equity Offering Participation Right** "). If Redmile exercises
its Future Equity Offering Participation Right, Redmile shall have the right to purchase up to a number of securities to be sold in such
Future Equity Offering equal to its pro rata percentage ownership in the Company (the "**Participation Percentage** ").
In the event of a firm commitment underwritten offering, the Company shall, in compliance with all applicable laws and regulations, use
commercially reasonable efforts to cause the Company's managing underwriter(s) to provide Redmile with the opportunity to purchase
shares of Common Stock offered to the public in such offering, at the same price per share at which such shares of Common Stock are sold
to the public in such offering, up to Redmile's Participation Percentage. For purposes of this Letter Agreement, "**Participation Percentage**" shall be calculated as a fraction, the numerator of which shall be equal to the number of shares of Common Stock
held by Redmile (including all shares of Common Stock then issuable (directly or indirectly) upon conversion of any pre-funded warrants,
common stock warrants and stock options beneficially owned by Redmile without regard to any beneficial ownership limitations) immediately
prior to the consummation of the Future Equity Offering, and the denominator of which shall be equal to the total number of outstanding
shares of Common Stock (including all shares of Common Stock issuable (directly or indirectly) upon conversion of all the pre-funded
warrants and common stock warrants then outstanding and all stock options beneficially owned by Redmile) immediately prior to the consummation
of the Future Equity Offering. Redmile may apportion its Future Equity Offering Participation Right among itself and its Affiliates in
such proportions as it deems appropriate. For the avoidance of doubt, nothing in this <u>Section 1</u> shall limit the number of securities
that Redmile or its Affiliates may acquire in a Future Equity Offering outside of its Future Equity Offering Participation Right nor
shall it obligate Redmile to participate in any Future Equity Offering.

2.  ***Board Observer Right.*** 

 ****

&nbsp;&nbsp;&nbsp;&nbsp;a. Beginning on the Closing Date and continuing until the earlier
to occur of (i) the date on which Redmile no longer beneficially owns at least 7.5% of the outstanding shares of Common Stock, but only
if such reduction in beneficial ownership is a result of transactions effected by Redmile (calculated in the same manner as the Participation
Percentage); or (ii) the date on which Redmile no longer beneficially owns at least 5% of the outstanding shares of Common Stock if such
reduction in beneficial ownership occurs for any reason (the "**Expiration Event** "), the Company shall invite a single
representative of Redmile (a "**Redmile Observer** "), as designated by Redmile from time to time, to attend and participate
in all meetings of the Board of Directors and any committees thereof in a nonvoting observer capacity. In this respect, the Company shall
give the Redmile Observer (i) written notice of, agendas and participation details for such meetings and (ii) copies of all notices,
minutes, consents, and other materials, including, without limitation, slide decks and presentations, in each case, that it provides
to the members of the Board of Directors or any committee thereof, as applicable, at the same time and in the same manner as provided
to such members; provided, however, that the Company reserves the right to withhold any information and to exclude the Redmile Observer
from any meeting or portion thereof if the Board of Directors determines in good faith and based upon the advice of outside counsel and
following reasonable notice to the Redmile Observer, that access to such information or attendance at such meeting could (x) adversely
affect the attorney-client privilege between the Company and its counsel or (y) result in a conflict of interest between the Company
and Redmile. If the Redmile Observer is so excluded, then, to the extent permissible under this Section, the Company will inform the
Redmile Observer of the general nature of the subject matter discussed and explain the Board's rationale for the decision to exclude
the Redmile Observer.

&nbsp;&nbsp;&nbsp;&nbsp;b. The Redmile Observer shall not, by virtue of his or her capacity as such, have
or be deemed to have, or otherwise be subject to, any duties (fiduciary or otherwise) to the Company or any of its Affiliates or subsidiaries
or its or their respective equityholders or any other Person or any duties (fiduciary or otherwise) otherwise applicable to the members
of the Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;c. The Company's obligations under this <u>Section 2</u> are contingent upon such Redmile Observer's (i) entering into a reasonable and mutually agreeable confidentiality agreement with the Company and (ii) agreeing, solely in such
individual's capacity as a Redmile Observer, to be bound by the Company's insider trading and window policies then in effect
and applicable to members of the Board of Directors.

3. Miscellaneous .

&nbsp;&nbsp;&nbsp;&nbsp;a.  ***Termination*** . This Agreement and the rights described
herein shall terminate and be of no further force or effect upon the earliest to occur of (a) the consummation of a merger or consolidation
of the Company that is effected (i) for independent business reasons unrelated to extinguishing such rights; and (ii) for purposes other
than the reincorporation of the Company in a different state; or (b) the Expiration Event; provided, that, in the case of Section 2 of
this Letter Agreement, the rights contained therein shall terminate in accordance with the terms thereof, and provided, further, in each
case, the confidentiality obligations referenced herein will survive any such termination.

&nbsp;&nbsp;&nbsp;&nbsp;b.  ***Conflict; Amendment; Waiver; Entire Agreement*** . In the event of any
conflict between the provisions of this Letter Agreement and the provisions of the Purchase Agreement, the provisions of this Letter Agreement
shall prevail and be given effect. Any term of this Letter Agreement may be amended, terminated or waived only with the written consent
of the Company and Redmile. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent
waiver of the same term or condition, or a waiver of any other term or condition of this Letter Agreement. The failure of either party
to assert any of its rights hereunder shall not constitute a waiver of such rights. This Letter Agreement, together with the Purchase
Agreement and the other transaction documents entered into in connection therewith, constitutes the full and entire understanding and
agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between the parties is expressly canceled.

&nbsp;&nbsp;&nbsp;&nbsp;c.  ***Miscellaneous.*** Section 8.2 (Notices), Section
8.3 (Consent to Electronic Notice), Section 8.4 (Severability), Section 8.5 (Governing Law; Submission to Jurisdiction; Venue; Waiver
of Trial by Jury), Section 8.8 (Assignment), Section 8.9 (Confidential Information), Section 8.13 (Headings), Section 8.14 (Counterparts),
Section 8.17 (Contract Interpretation) and Section 8.18 (Arm's Length Negotiations) of the Purchase Agreement are incorporated
by reference herein, *mutatis mutandis*.

*[Signature pages follow]*

 

**IN WITNESS WHEREOF**, the parties have executed this Letter Agreement as of the date first set forth above.

---

| | |
|:---|:---|
| **COMPANY:**<br>**SHATTUCK LABS, INC.** | **COMPANY:**<br>**SHATTUCK LABS, INC.** |
| By: | /s/ Andrew Neill |
| Name: Andrew Neill | Name: Andrew Neill |
| Title: Chief Financial Officer | Title: Chief Financial Officer |

---

*[Signature page to Redmile Side Letter]*

**IN WITNESS WHEREOF**, the parties have executed this Letter Agreement as of the date first set forth above.

---

| | |
|:---|:---|
| **REDMILE GROUP, LLC** | **REDMILE GROUP, LLC** |
| By: | /s/ Joshua Garcia |
| Name: Joshua Garcia | Name: Joshua Garcia |
| Title: Authorized Signatory | Title: Authorized Signatory |

---

*[Signature page to Redmile Side Letter]*

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Shattuck Labs, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**82024L103**

*(CUSIP Number)*

**Redmile Group, LLC**<br>Attn: Joshua Garcia<br>One Letterman Drive Bldg D, Ste D3-300<br>San Francisco CA 94129<br>(415) 489-9980

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/04/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **82024L103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Redmile Group, LLC** | Name of reporting person<br>**Redmile Group, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5652660.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5652660.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5652660.00** | Aggregate amount beneficially owned by each reporting person<br>**5652660.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.8%** | Percent of class represented by amount in Row (11)<br>**11.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** (1) The source of funds was working capital of certain private investment funds managed by Redmile Group, LLC (the "Redmile Funds"), including Redmile Biopharma Investments II, L.P. ("RBI II").

(2) The aggregate amount of shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that may be deemed beneficially owned by Redmile Group, LLC ("Redmile") are held directly by the Redmile Funds, including RBI II. Redmile as the investment manager to each Redmile Fund exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

(3) Percent of class calculated based on: 47,903,215 shares of Common Stock outstanding on May 14, 2025, as disclosed in the Issuer's Definitive Proxy Statement for the 2025 Annual Meeting of the Stockholders filed on Schedule 14A with the SEC on May 21, 2025 (the "Proxy Statement").

| **CUSIP No.** | **82024L103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jeremy C. Green** | Name of reporting person<br>**Jeremy C. Green** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X0** | Citizenship or place of organization<br>**X0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5652660.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5652660.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5652660.00** | Aggregate amount beneficially owned by each reporting person<br>**5652660.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.8%** | Percent of class represented by amount in Row (11)<br>**11.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) The source of funds was working capital of the Redmile Funds, including RBI II.

(2) The aggregate amount of shares of the Common Stock that may be deemed beneficially owned by Jeremy C. Green are held directly by the Redmile Funds, including RBI II. Redmile as the investment manager to each Redmile Fund exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Mr. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

(3) Percent of class calculated based on: 47,903,215 shares of Common Stock outstanding on May 14, 2025, as disclosed in the Proxy Statement.

| **CUSIP No.** | **82024L103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Redmile Biopharma Investments II, L.P.** | Name of reporting person<br>**Redmile Biopharma Investments II, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3338997.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3338997.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3338997.00** | Aggregate amount beneficially owned by each reporting person<br>**3338997.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.0%** | Percent of class represented by amount in Row (11)<br>**7.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** (1) Percent of class calculated based on: 47,903,215 shares of Common Stock outstanding on May 14, 2025, as disclosed in the Proxy Statement.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Shattuck Labs, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
500 W. 5th Street, Austin, TX, 78701

**Item 4. Purpose of Transaction**

The information in Item 6 below is incorporated herein by reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

(a) The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons is comprised of the following: (i) 456,784 shares of Common Stock held by Redmile Capital Fund, L.P., (ii) 494,932 shares of Common Stock held by Redmile Capital Offshore Master Fund, Ltd., (iii) 374,149 shares of Common Stock held by Redmile Capital Offshore II Master Fund, Ltd., (iv) 301,022 shares of Common Stock  held by Redmile Strategic Long Only Trading Sub, Ltd., (v) 467,910 shares of Common Stock held by Redmile Strategic Trading Sub, Ltd., (vi) 3,338,997 shares of Common Stock  held by RBI II, and (vii) 105,930 shares of Common Stock held by RedCo I, L.P.  Redmile is the investment manager to each of the private investment funds listed in items (i) through (vii) (the "Redmile Funds") and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such shares, if any.

Subject to the Beneficial Ownership Blocker (as defined below), Redmile and Mr. Green may also be deemed to beneficially own 3,100,823 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. Pursuant to the terms of the Pre-Funded Warrants, the Common Stock that may be acquired upon exercise of the Pre-Funded Warrants shall be limited to the extent that, following such exercise, the total number of shares of Common Stock then beneficially owned by the holder of the Pre-Funded Warrants, together with such holder's affiliates and any other person whose beneficial ownership of Common Stock would be aggregated with such holder's for the purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), would exceed the Beneficial Ownership Limitation (the "Beneficial Ownership Blocker"). The "Beneficial Ownership Limitation" is 9.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. Because the percentage of shares of Common Stock held directly by the Redmile Funds at the time of this filing exceeds 9.99% in the aggregate, the exercise of the Pre-Funded Warrants held by Redmile Funds are limited in their entirety by the Beneficial Ownership Blocker and the Reporting Persons therefore cannot be deemed to have beneficial ownership of any of the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and such shares have not been included in the aggregate amount of securities reported in this Schedule 13D.

Redmile and Mr. Green may also be deemed to beneficially own 112,936 shares of Common Stock subject to options to purchase shares of Common Stock that are exercisable within 60 days of the date of this filing. The stock options were granted to Mike Lee, a managing director of Redmile, in connection with his service as a member of the Board of Directors. Pursuant to the policies of Redmile, Mr. Lee holds the stock options as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock options to Redmile.

For purposes of this Schedule 13D, the percent of class is calculated based on 47,903,215 shares of Common Stock outstanding on May 14, 2025, as disclosed in the Proxy Statement.

**(b)**
Redmile Group, LLC:
(1) Sole Voting Power: 0
(2) Shared Voting Power: 5,652,660
(3) Sole Dispositive Power: 0
(4) Shared Dispositive Power: 5,652,660

Jeremy C. Green:
(1) Sole Voting Power: 0
(2) Shared Voting Power: 5,652,660
(3) Sole Dispositive Power: 0
(4) Shared Dispositive Power: 5,652,660

Redmile Biopharma Investments II, L.P.:
(1) Sole Voting Power: 0
(2) Shared Voting Power: 3,338,997
(3) Sole Dispositive Power: 0
(4) Shared Dispositive Power: 3,338,997

**(c)**
—

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Prior Schedule 13D is hereby amended and supplemented by replacing the last paragraph of Item 6 with the following paragraphs:

Securities Purchase Agreement

On August 4, 2025, the Issuer entered into a securities purchase agreement with certain institutional accredited investors (the "Purchase Agreement"), including RBI II and certain other Redmile Funds. Pursuant to the terms of the Purchase Agreement, the Issuer will issue and sell to RBI II and certain other Redmile Funds in a private placement Pre-Funded Warrants to purchase up to an aggregate of 4,097,730 shares of Common Stock, each with an exercise price of $0.0001 per Pre-Funded Warrant, and accompanying warrants (the "Common Warrants") to purchase up to an aggregate of 4,097,730 shares of Common Stock, each with an exercise price of $1.0846 per Common Warrant, at a combined price of $0.8676, upon the closing of the transaction. Of the warrants to be issued and sold to the Redmile Funds in the private placement, RBI II will purchase Pre-Funded Warrants to purchase up to an aggregate of 2,048,423 shares of Common Stock and Common Warrants to purchase up to an aggregate of 2,048,423 shares of Common Stock upon the closing of the transaction. The closing of the private placement is subject to the satisfaction or waiver of certain material conditions specified in the Purchase Agreement, including the regulatory clearance of the Issuer's investigational new drug application by the U.S. Food and Drug Administration prior to the closing.

The foregoing summary of the Purchase Agreement is not intended to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed as Exhibit 99.7 to this Schedule 13D and is incorporated herein by reference.

Side Letter Agreement

In connection with the execution of the Purchase Agreement, Redmile also entered into a side letter agreement with the Issuer, dated as of August 4, 2025 (the "Side Letter").  Pursuant to the terms of the Side Letter, upon the closing of the private placement, Redmile will have (a) the right to participate in future equity offerings of the Issuer up to its pro rata ownership percentage in the Issuer, and (b) the right to designate a non-voting observer to the Issuer's Board of Directors subject to Redmile maintaining a certain beneficial ownership interest in the Issuer's Common Stock.

The foregoing summary of the Side Letter is not intended to be complete and is qualified in its entirety by reference to the full text of the Side Letter, which is filed as Exhibit 99.8 to this Schedule 13D and is incorporated herein by reference.

Except as described above, no contracts, arrangements, understandings, or relationships (legal or otherwise) exist between any Reporting Person and any person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies. Except as described above, none of the Reporting Persons is a party to any arrangement whereby securities of the Issuer are pledged or are otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Redmile Group, LLC

**Signature:** /s/ Jeremy C. Green

**Name/Title:** Managing Member

**Date:** 08/06/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jeremy C. Green

**Signature:** /s/ Jeremy C. Green

**Name/Title:** Jeremy C. Green

**Date:** 08/06/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Redmile Biopharma Investments II, L.P.

**Signature:** /s/ Jeremy C. Green

**Name/Title:** Managing Member of Redmile Group, LLC, the Managing Member of Redmile Biopharma Investments II (GP), LLC, its General Partner

**Date:** 08/06/2025